Prognostic impact of p53 and p63 immunoexpression in oral squamous cell carcinoma

Journal of Oral Pathology and Medicine

Volumn 36, Issue 4, 2007, Pages 191-197

  De Oliveira, Lucinei Roberto ^a   Ribeiro Silva, Alfredo ^a   Zucoloto, Sérgio ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Immunohistochemistry; Oral cancer; Oral squamous cell carcinoma; p53; p63; Prognosis

Indexed keywords

PROTEIN P53; PROTEIN P56;

ADULT; ARTICLE; CANCER LOCALIZATION; CANCER RECURRENCE; CANCER SURVIVAL; CELL DIFFERENTIATION; CONTROLLED STUDY; DISEASE FREE SURVIVAL; EMBEDDING; FEMALE; HISTOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; METASTASIS; MOUTH CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA; TISSUE DIFFERENTIATION;

CARCINOMA, SQUAMOUS CELL; DISEASE-FREE SURVIVAL; DNA-BINDING PROTEINS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; MOUTH NEOPLASMS; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; STATISTICS, NONPARAMETRIC; TRANS-ACTIVATORS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS;

EID: 33947691570     PISSN: 09042512     EISSN: 16000714     Source Type: Journal    
DOI: 10.1111/j.1600-0714.2007.00517.x     Document Type: Article

References (49)

1. Nylander K, Dabelsteen E, Hall PA. The p53 molecule and its prognostic role in squamous cell carcinomas of the head and neck. J Oral Pathol Med 2000; 29: 413-25.
2. Garcia-Montesinos-Perea B, Val-Bernal JF, Saiz-Bustillo R. Epidermoid carcinoma of the lip: an immunohistochemical study. Med Oral Patol Oral Cir Bucal 2005; 10: 454-61.
3. Varley JM, Brammar WJ, Lane DP, Swallow JE, Dolan C, Walker RA. Loss of chromosome 17p13 sequences and mutation of p53 in human breast carcinomas. Oncogene 1991; 6: 413-21.
4. Macgeoch C, Barnes DM, Newton JA et al. p53 protein detected by immunohistochemical staining is not always mutant. Dis Markers 1993; 11: 239-50.
5. Xu L, Chen YT, Huvos AG et al. Overexpression of p53 protein in squamous cell carcinomas of head and neck without apparent gene mutations. Diagn Mol Pathol 1994; 3: 83-92.
6. Sauter ER, Ridge JA, Gordon J, Eisenberg BL. p53 overexpression correlates with increased survival in patients with squamous carcinoma of the tongue base. Am J Surg 1992; 164: 651-53.
7. Gapany M, Pavelic ZP, Gapany SR et al. Relationship between immunohistochemically detectable p53 protein and prognostic factors in head and neck tumors. Cancer Detect Prev 1993; 17: 379-86.
8. Raybaud-Diogène H, Tètu B, Morency R, Fortin A, Monteil RA. p53 overexpression in head and neck squamous cell carcinoma: review of the literature. Eur J Cancer B Oral Oncol 1996; 32B: 143-49.
9. Sittel C, Ruiz S, Volling P, Kvasnicka HM, Jungehulsing M, Eckel HE. Prognostic significance of Ki-67 (MIB1), PCNA and p53 in cancer of the oropharynx and oral cavity. Oral Oncol 1999; 35: 583-89.
10. Grabenbauer GG, Muhlfriedel C, Rodel F et al. Squamous cell carcinoma of the oropharynx: Ki-67 and p53 can identify patients at high risk for local recurrence after surgery and postoperative radiotherapy. Int J Radiat Oncol Biol Phys 2000; 48: 1041-50.
11. Gonzalez-Moles MA, Galindo P, Gutierrez-Fernandez J et al. P53 protein expression in oral squamous cell carcinoma survival analysis. Anticancer Res 2001; 21(4B): 2889-94.
12. Narayana A, Vaughan AT, Gunaratne S, Kathuria S, Walter SA, Reddy SP. Is p53 an independent prognostic factor in patients with laryngeal carcinoma? Cancer 1998; 82: 286-91.
13. Vielba R, Bilbao J, Ispizua A et al. p53 and cyclin D1 as prognostic factors in squamous cell carcinoma of the larynx. Laryngoscope 2003; 113: 167-72.
14. Sauter ER, Ridge JA, Litwin S, Langer CJ. Pretreatment p53 protein expression correlates with decreased survival in patients with end-stage head and neck cancer. Clin Cancer Res 1995; 1: 1407-12.
15. Thurfjell N, Coates PJ, Boldrup L et al. Function and importance of p63 in normal oral mucosa and squamous cell carcinoma of the head and neck. Adv Otorhinolaryngol 2005; 62: 49-57.
16. Yang A, Kaghad M, Wang Y et al. p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities. Mol Cell 1998; 2: 305-16.
17. Ghioni P, Bolognese F, Duijf PH, Van Bokhoven H, Mantovani R, Guerrini L. Complex transcriptional effects of p63 isoforms: identification of novel activation and repression domains. Mol Cell Biol 2002; 22: 8659-68.
18. Reis-Filho JS, Torio B, Albergaria A, Schmitt FC. p63 expression in normal skin and usual cutaneous carcinomas. J Cutan Pathol 2002; 29: 517-23.
19. Lo Muzio L, Santarelli A, Caltabiano R et al. p63 overexpression associates with poor prognosis in head and neck squamous cell carcinoma. Hum Pathol 2005; 36: 187-94.
20. Parsa R, Yang A, Mckeon F, Green H. Association of p63 with proliferative potential in normal and neoplastic human keratinocytes. J Invest Dermatol 1999; 113: 1099-105.
21. Hibi K, Trink B, Patturajan M et al. Ais is an oncogene amplified in squamous cell carcinoma. Proc Natl Acad Sci USA 2000; 97: 5462-67.
22. Di Como CJ, Urist MJ, Babayan I et al. p63 expression profiles in human normal and tumor tissues. Clin Cancer Res 2002; 8: 494-501.
23. Wang TY, Chen BF, Yang YC et al. Histologic and immunophenotypic classification of cervical carcinomas by expression of the p53 homologue p63: a study of 250 cases. Hum Pathol 2001; 32: 479-86.
24. Choi HR, Batsakis JG, Zhan F, Sturgis E, Luna MA, EL-Naggar AK. Differential expression of p53 gene family members p63 and p73 in head and neck squamous tumorigenesis. Hum Pathol 2002; 33: 158-64.
25. Weber A, Bellmann U, Bootz F, Wittekind C, Tannapfel A. Expression of p53 and its homologues in primary and recurrent squamous cell carcinomas of the head and neck. Int J Cancer 2002; 99: 22-8.
26. Zigeuner R, Tsybrovskyy O, Ratschek M, Rehak P, Lipsky K, Langner C. Prognostic impact of p63 and p53 expression in upper urinary tract transitional cell carcinoma. Urology 2004; 63: 1079-1083.
27. Association of Directors of Anatomic and surgical Pathology. Recommendations for the reporting of specimens containing oral cavity and oropharynx neoplasms. Virchows Arch 2000; 437: 345-47.
28. Wahi PN, Cohen B, Luthra UK et al. Histological consideration. In: Wahi PN, Cohen B, Luthra UK et al., eds. Histological typing of oral and oropharyngeal tumors. Geneva, Switzerland: World Health Organization, 1977; 15-19.
29. Ord RA. Discussion. Primary oral squamous cell carcinoma: a review of 92 cases. J Oral Maxillofac Surg 1996; 54: 955.
30. Sobin LH, Wittekind CH. TNM classification of malignant tumors. New York: Wiley-Liss, 1997.
31. De Vicente JC, Junqueira LM, Zapatero AH, Forcelledo MF, Hernández-Vallejo G, Arranz JS. Prognostic significance of p53 expression in oral squamous cell carcinoma without neck node metastases. Head Neck 2004; 26: 22-30.
32. Ramalho LN, Maggiori MS, Ribeiro-Silva A, Peres LC. P63 expression in hydropic abortion and gestational trophoblastic diseases. Placenta 2006; 27: 740-43.
33. Massion PP, Taflan PM, Jamshedur Rahman SM et al. Significance of p63 amplification and overexpression in lung cancer development and prognosis. Cancer Res 2003; 63: 7113-21.
34. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-81.
35. Ha PK, Califano JA. The role of human papillomavirus in oral carcinogenesis. Crit Rev Oral Biol Med 2004; 15: 188-96.
36. Brachman DG, Graves D, Vokes E et al. Occurrence of p53 gene deletions and human papilloma virus infection in human head and neck cancer. Cancer Res 1992; 52: 4832-36.
37. Ahomadegbe JC, Barrois M, Fogel S et al. High incidence of p53 alterations (mutation, deletion, overexpression) in head and neck primary tumors and metastases; absence of correlation with clinical outcome. Frequent protein overexpression in normal epithelium and in early non-invasive lesions. Oncogene 1995; 10: 1217-27.
38. Khademi B, Shirazi FM, Vasei M et al. The expression of p53, c-erbB-1 and c-erbB-2 molecules and their correlation with prognostic markers in patients with head and neck tumors. Cancer Lett 2002; 184: 223-30.
39. Unal OF, Ayhan A, Hosal AS. Prognostic value of p53 expression and histopathological parameters in squamous cell carcinoma of oral tongue. J Laryngol Otol 1999; 113: 446-50.
40. Siegelmann-Danieli N, Ben-Izhack O, Hanlon A et al. P53 alteration in oral tongue cancer is not significantly associated with age at diagnosis or tobacco exposure. Tumori 2005; 91: 346-50.
41. Bortoluzzi MC, Yurgel LS, Dekker NP, Jordan RC, Regezi JA. Assessment of p63 expression in oral squamous cell carcinomas and dysplasias. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2004; 98: 698-704.
42. Hagiwara K, Mcmenamin MG, Miura K, Harris CC. Mutational analysis of the p63/p73L/p51/p40/CUSP/KET gene in human cancer cell lines using intronic primers. Cancer Res 1999; 59: 4165-69.
43. Nylander K, Vojtesek B, Nenutil R et al. Differential expression of p63 isoforms in normal tissues and neoplastic cells. J Pathol 2002; 198: 417-27.
44. Crook T, Nicholls JM, Brooks L, O'nions J, Allday MJ. High level expression of ▽N-p63: a mechanism for the inactivation of p53 in undifferentiated carcinoma. Oncogene 2000; 19: 3439-44.
45. Pellegrini G, Dellambra E, Golisano O et al. p63 identifies keratinocyte stem cells. Proc Natl Acad Sci USA 2001; 98: 3156-61.
46. Foschini MP, Gaiba A, Cocchi R et al. Pattern of p63 expression in squamous cell carcinoma of the oral cavity. Virchows Arch 2004; 444: 332-9.
47. Takahashi Y, Noguchi T, Takeno S, Kimura Y, Okubo M, Kawahara K. Reduced expression of p63 has prognostic implications for patients with esophageal squamous cell carcinoma. Oncol Rep 2006; 15: 323-28.
48. Urist MJ, Di Como CJ, LU ML et al. Loss of p63 expression is associated with tumor progression in bladder cancer. Am J Pathol 2002; 161: 1199-206.
49. Koga F, Kawakami S, Fujii Y et al. Impaired p63 expression associates with poor prognosis and uroplakin III expression in invasive urothelial carcinoma of the bladder. Clin Cancer Res 2003; 9: 5501-7.